Enliven Therapeutics, Inc. (ELVN) Earnings Call Transcripts

Enliven Therapeutics, Inc.'s Latest Earnings Call - June 11, 2026

In the June 2026 earnings call, Enliven Therapeutics (ELVN:US) provided a significant update on its lead program, ELVN-001, a potential best-in-class treatment for chronic myeloid leukemia (CML). The company reported a 48% major molecular response (MMR) rate at the 80 mg dose in a heavily pretreated patient population, which is notably higher than the 24% MMR seen with asciminib in a less heavily pretreated cohort. Management is on track to initiate a Phase III trial in the second-line plus CML setting by year-end, having received positive feedback from the FDA regarding trial design and dosing. Financially, the company is well-capitalized, with sufficient cash to fund operations through 2029, supporting their aggressive development plans.

Reported metrics

Guidance from management

Management is on track to initiate a Phase III trial in the second-line plus setting by year-end 2026, with plans for a Phase II study in newly diagnosed patients starting in 2027.

What management said

All right. It looks like Dr. Kim, we have some questions already rolling in for you. I think it's phrased in a couple of different ways, but maybe can you discuss your view of the data, what stands out to you compared to other drugs or what stands out to you from the data that are presented today?

I think that the beauty of ELVN-001 is tolerability or tolerability, which make us to continue the treatment, which is durability and which will increase the efficacy. So I think that these are the combination. It's not just the one. However, I have to emphasize that it doesn't have an excellent tolerability because of that, we can increase the efficacy and the patient can continue their treatment and in future maybe...

What analysts pressed on

Analysts expressed concerns about the competitive landscape, particularly regarding the efficacy of ELVN-001 compared to other emerging therapies like asciminib and TERN-701. There were also questions about the long-term safety profile and how it will hold up against established treatments.

Main topics on the call

• Clinical Data Update — Enliven reported a 48% MMR rate at the 80 mg dose in the ENABLE Phase I study, indicating strong efficacy in a heavily pretreated population. Management stated, "We believe this clinical profile positions ELVN-001 to com...
• FDA Interaction and Phase III Plans — The company successfully completed an end of Phase I meeting with the FDA, aligning on key elements for the Phase III trial. They plan to initiate this trial in the second-line plus setting before year-end, which managem...
• Safety and Tolerability Profile — ELVN-001 demonstrated a favorable safety profile, with only 6% of patients discontinuing due to adverse events. Management highlighted that "the safety profile remains impressive and appears differentiated from all the a...
• Market Opportunity — Management emphasized the significant market potential for CML treatments, estimating a $10 billion opportunity in the U.S. split between first-line and second-line plus populations. They noted, "We expect ELVN-001 will ...

Read the full Enliven Therapeutics, Inc. transcript (June 11, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 1 Enliven Therapeutics, Inc. earnings call transcript on record, spanning June 11, 2026 to June 11, 2026. The most recent call on file is dated June 11, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ELVN

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

1

First call

June 11, 2026

Most recent

June 11, 2026